Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2017 Mar 3

PMID 28250576

Citations 24

Authors

Maria H Madeira

Raquel Boia

Antonio F Ambrosio

Ana R Santiago

Affiliations

Soon will be listed here.

Abstract

Caffeine is the major component of coffee and the most consumed psychostimulant in the world and at nontoxic doses acts as a nonselective adenosine receptor antagonist. Epidemiological evidence suggests that caffeine consumption reduces the risk of several neurological and neurodegenerative diseases. However, despite the beneficial effects of caffeine consumption in human health and behaviour, the mechanisms by which it impacts the pathophysiology of neurodegenerative diseases still remain to be clarified. A promising hypothesis is that caffeine controls microglia-mediated neuroinflammatory response associated with the majority of neurodegenerative conditions. Accordingly, it has been already described that the modulation of adenosine receptors, namely, the A receptor, affords neuroprotection through the control of microglia reactivity and neuroinflammation. In this review, we will summarize the main effects of caffeine in the modulation of neuroinflammation in neurodegenerative diseases.

Citing Articles

Neuroprotective efficacy of berberine and caffeine against rotenone-induced neuroinflammatory and oxidative disturbances associated with Parkinson's disease via inhibiting α-synuclein aggregation and boosting dopamine release.

Waheeb T, Abdulkader M, Ghareeb D, Moustafa M Inflammopharmacology. 2025; .

PMID: 40057928 DOI: 10.1007/s10787-025-01661-w.

Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson's Disease?.

Koukoulis T, Beauchamp L, Kaparakis-Liaskos M, McQuade R, Purnianto A, Finkelstein D J Parkinsons Dis. 2024; 14(2):227-244.

PMID: 38427502 PMC: 10977405. DOI: 10.3233/JPD-230315.

Interplay between microglia and environmental risk factors in Alzheimer's disease.

Zhang M, Liang C, Chen X, Cai Y, Cui L Neural Regen Res. 2023; 19(8):1718-1727.

PMID: 38103237 PMC: 10960290. DOI: 10.4103/1673-5374.389745.

Molecular Aspects of a Diet as a New Pathway in the Prevention and Treatment of Alzheimer's Disease.

Doroszkiewicz J, Mroczko J, Rutkowski P, Mroczko B Int J Mol Sci. 2023; 24(13).

PMID: 37445928 PMC: 10341644. DOI: 10.3390/ijms241310751.

Caffeine for Prevention of Alzheimer's Disease: Is the A Adenosine Receptor Its Target?.

Merighi S, Travagli A, Nigro M, Pasquini S, Cappello M, Contri C Biomolecules. 2023; 13(6).

PMID: 37371547 PMC: 10296091. DOI: 10.3390/biom13060967.

References

Ikeda K, Kurokawa M, Aoyama S, Kuwana Y . Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem. 2002; 80(2):262-70. DOI: 10.1046/j.0022-3042.2001.00694.x. View

Haskell C, Kennedy D, Wesnes K, Scholey A . Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl). 2005; 179(4):813-25. DOI: 10.1007/s00213-004-2104-3. View

Mayne M, Shepel P, Jiang Y, Geiger J, Power C . Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol. 1999; 45(5):633-9. DOI: 10.1002/1531-8249(199905)45:5<633::aid-ana12>3.0.co;2-x. View

Chen J, Xu K, Petzer J, Staal R, Xu Y, Beilstein M . Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001; 21(10):RC143. PMC: 6762498. View

Shemer A, Jung S . Differential roles of resident microglia and infiltrating monocytes in murine CNS autoimmunity. Semin Immunopathol. 2015; 37(6):613-23. DOI: 10.1007/s00281-015-0519-z. View

Gu L, Gonzalez F, KALOW W, Tang B . Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics. 1992; 2(2):73-7. DOI: 10.1097/00008571-199204000-00004. View

Hasko G, Pacher P . Regulation of macrophage function by adenosine. Arterioscler Thromb Vasc Biol. 2012; 32(4):865-9. PMC: 3387535. DOI: 10.1161/ATVBAHA.111.226852. View

Chen J, Chern Y . Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. Handb Exp Pharmacol. 2010; (200):267-310. DOI: 10.1007/978-3-642-13443-2_10. View

Xu K, Xu Y, Chen J, Schwarzschild M . Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett. 2002; 322(1):13-6. DOI: 10.1016/s0304-3940(02)00069-1. View

10.

Chen Z, Trapp B . Microglia and neuroprotection. J Neurochem. 2015; 136 Suppl 1:10-7. DOI: 10.1111/jnc.13062. View

11.

Bjorklund O, Shang M, Tonazzini I, Dare E, Fredholm B . Adenosine A1 and A3 receptors protect astrocytes from hypoxic damage. Eur J Pharmacol. 2008; 596(1-3):6-13. DOI: 10.1016/j.ejphar.2008.08.002. View

12.

Biber K, Owens T, Boddeke E . What is microglia neurotoxicity (Not)?. Glia. 2014; 62(6):841-54. DOI: 10.1002/glia.22654. View

13.

Ingwersen J, Wingerath B, Graf J, Lepka K, Hofrichter M, Schroter F . Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. J Neuroinflammation. 2016; 13:48. PMC: 4768407. DOI: 10.1186/s12974-016-0512-z. View

14.

Blackburn M, Vance C, Morschl E, Wilson C . Adenosine receptors and inflammation. Handb Exp Pharmacol. 2009; (193):215-69. DOI: 10.1007/978-3-540-89615-9_8. View

15.

Hirsch E, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel P . The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci. 2003; 991:214-28. DOI: 10.1111/j.1749-6632.2003.tb07478.x. View

16.

Wu Y, Dissing-Olesen L, MacVicar B, Stevens B . Microglia: Dynamic Mediators of Synapse Development and Plasticity. Trends Immunol. 2015; 36(10):605-613. PMC: 4841266. DOI: 10.1016/j.it.2015.08.008. View

17.

Mikami Y, Yamazawa T . Chlorogenic acid, a polyphenol in coffee, protects neurons against glutamate neurotoxicity. Life Sci. 2015; 139:69-74. DOI: 10.1016/j.lfs.2015.08.005. View

18.

Jenner P . Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord. 1998; 13 Suppl 1:24-34. View

19.

Hauser R, Stocchi F, Rascol O, Huyck S, Capece R, Ho T . Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol. 2015; 72(12):1491-500. DOI: 10.1001/jamaneurol.2015.2268. View

20.

Wang T, Xi N, Chen Y, Shang X, Hu Q, Chen J . Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism. Neuropharmacology. 2014; 86:203-11. DOI: 10.1016/j.neuropharm.2014.06.029. View